This mechanism seems reasonable because inhibition of SRC kinase activity antagonized the protection role of secreted GRP78 on HCC cells upon sorafenib treatment and inhibited the phosphorylation of STAT3 in HCC cells simultaneously. This evidence concerns the gene STAT3 and hepatocellular carcinoma.